Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
"Given the rapidity, full automation, and practical advantages of the Idylla SARS-CoV-2 assay, pooling of 10 samples has the potential to significantly increase testing capacity for both NPS and saliva samples, with good sensitivity."
If ArgenX can serve as an example, their recent FDA approval for Efgartigimod generated a +/-13% SP gain. Applying the same logic to Biocartis' long-awaited FDA approval, we can hardly expect a SP of 4€. I know both are not comparable, but nevertheless not really comforting :-(
The main reason why the share is being pulled down, is because a great amount is being shorted. This has also a lot to do with the convertibles that are still standing till 2024. Only a massive increase in sales and production can turn this around. That is why we were looking forward towards the 60% growth that was promised this year, strong growth that is necessary to become profitable. What can they deliver and also what is the next step to keep the car running.
Looking at the short positions published by FSMA, I see only 2 positions: Citadel EU 1% unchanged since 18/12/2020 and Millenium Capital Partners 0.60% since 25/05/2021. At that time Biocartis SP was still at 3.90 -4.00€. What can bring the SP back to 4.50 let alone 5.00€ mark? FDA approval (last time one test was approved, all SP gains disappeared in less than 3 days). More sales? Sure, always helpfull. New tests on the platform ? I feel Rudi Pauwels was paying much more attentioan at PR around achievements, no matter how big or how small. Now, events come and go, nobody notices, which is letal for a small cap like Biocartis.
De Shortpositie op 23 december 2021 is 3,13%. 2,53% voor rekening van Citadel Europe en 0,60% voor rekening van Millenium International Management.
Gaan we weer zakken naar €3,00 (17/03/2020) ? om dan in iets meer dan een maand door te stijgen naar €5,60 (24/03/2020). Het zou mooie zijn. Dr Zoot Uw bemerking "Nu komen en gaan gebeurtenissen, niemand merkt het, wat dodelijk is voor een smallcap als Biocartis" is terecht maar toch zijn er uitzonderingen. Neem nu in smallcap "Greenyard" eveneens door zeer zware stormen moet gaan maar er vandaag toch staat. Greenyard betaalde op 22 december 2021 zijn converteerbare obligatie lening van €125.000.000 terug. Een schuldeninstrument met een rente van 3,75%. De converteerbare obligatie van Biocartis vervaldatum 2024 is een schuldeninstrument met een rente van 4%. Het is dan ook zeer moeilijk te voorspellen welke richting het zal uitgaan maar tot op vandaag en dit al drie jaar lang is de richting naar beneden .
Brand new article discussing use of Idylla as a screening test before NGS Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations Abstract: Epidermal growth factor receptor (EGFR) genotyping, a critical examen for the treatment decisions of patients with non-small cell lung cancer (NSCLC), is commonly assayed by next-generation sequencing (NGS), but this global approach takes time. To determine whether rapid EGFR genotyping tests by the IdyllaTM system guides earlier therapy decisions, EGFR mutations were assayed by both the IdyllaTM system and NGS in 223 patients with NSCLC in a bicentric prospective study. IdyllaTM demonstrated agreement with the NGS method in 187/194 cases (96.4%) and recovered 20 of the 26 (77%) EGFR mutations detected using NGS. Regarding the seven missed EGFR mutations, five were not detected by the IdyllaTM system, one was assayed in a sample with insufficient tumoral cells, and the last was in a sample not validated by the IdyllaTM system (a bone metastasis). IdyllaTM did not detect any false positives. The average time between eGFR genotyping results from IdyllaTM and the NGS method was 9.2 ± 2.2 working days (wd) (12.6 ± 4.0 calendar days (cd)). Subsequently, based on the IdyllaTM method, the timeframe from tumor sampling to the initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd), while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) with the NGS method (p < 0.001). We thus demonstrated here that the IdyllaTM system contributes to improving the therapeutic care of patients with NSCLC by the early screening of EGFR mutations. -------------------- Tumor sampling to initiation of EGFR-TKIs was reduced by two weeks when the decision was based on the IdyllaTM method compared to when the decision was based on the NGS method. This has always been my investment thesis for Biocartis.. One day it'll be standard way of testing imo.
So once more promising news.
Oz This statement appears to be erroneous/ "The average time between eGFR genotyping results from IdyllaTM and the NGS method was 9.2 ± 2.2 working days (wd) (12.6 ± 4.0 calendar days (cd)). Subsequently, based on the IdyllaTM method, the timeframe from tumor sampling to the initiation of EGFR-TKI was 7.7 ± 1.2 wd (11.4 ± 3.1 cd), while it was 20.3 ± 6.7 wd (27.2 ± 8.3 cd) with the NGS method (p < 0.001). " How can the ave time to treatment be 7.7 days using Idylla when the ave turnaround of results is 9.2 days? The statement says a lot about the bureaucracy of these facilities. We all know Idylla provides results in hours not a week. Considerable time is lost in the way Idylla is being used (i.e, interfacing between the lab technician and the oncologist). This can be improved by moving idylla closer to the oncologist. Finally the fact that Idylla recovered only 20 of the 26 (77%) EGFR mutations detected using NGS is concerning. We know from the paper released earlier this year that most if not all of this discrepancy is due to missed T790M mutations. Unfortunately, this is one of the most common NSCLC mutations and is critical for for prescribing Tagrisso, one of the best selling treatment drugs (and one of the largest products of our partner AZN). The technical articles I read indicate the problem is an incorrect amplification curve for this mutation. It is correctable and I've discussed it with Renate a year ago. This problem was to be resolved in the BRAF-EGFR assay that was supposed to be released this year. Well they kicked the release of this assay back to 2022. Perhaps they are using the constrained product release after the fire as an opportunity to clear the market of the Old EGFR test before launching the new one. This is my growing frustration w Biocartis, They do not act with any urgency. They double the headcount but they are no better at R&D then they were 4 years ago. The analyst community in Belgium really does not apply pressure to get answers. I still think there is a large market for automating MDx but BCART needs to demonstrate that they can execute in delivering on the promise of Idylla. FL
Merry Christmas FL, The analysis time includes tumor sampling to histological analysis which takes 5.3 +- 3.6 working days and then it's egfr request (decision making) to actual analysis on the Idylla which takes 1.5 +- 1.3 working days as opposed to 10.3 +- 2 working days when it's NGS. The study is taking a holistic approach. As tumor samples are precious samples, there'll be extra steps ensuring right test is ordered etc... Hope we'll see a turnaround story for Biocartis in 2022!
OzDx schreef op 24 december 2021 23:30 :
Merry Christmas FL,
The analysis time includes tumor sampling to histological analysis which takes 5.3 +- 3.6 working days and then it's egfr request (decision making) to actual analysis on the Idylla which takes 1.5 +- 1.3 working days as opposed to 10.3 +- 2 working days when it's NGS.
The study is taking a holistic approach. As tumor samples are precious samples, there'll be extra steps ensuring right test is ordered etc...
Hope we'll see a turnaround story for Biocartis in 2022!
Oz Thanks for the explanation, I know that sample volume is a huge issue. I've read a couple articles about protocols for using the cytology smear samples after deinking. If this procedure can be refined it would make it easier to incorporate Idylla into a labs workflow. The other point I always like to see emphasized in these studies is that Idylla has typically been able to return actionable results for many samples that did not have sufficient suitable DNA for NGS analysis. The MSK study emphasized this as an important feature of Idylla. I hate to keep harping on the mutation amplification issue but it has to be of extreme importance to our largest pharma partner and given the higher EGFR mutation prevalence in Asian populations, I believe it is critical before launching in China and Japan. I also hope for a turnaround in 2022. I keep saying that I think BCART is flying way below the radar of most MDx investors and has the potential for the stars finally aligning to get critical registration approvals at the same time the world emerges from the pandemic (or at least when it becomes endemic). Regards to you, Best wishes for a great 2022! FL
Hey all, before leaving on a break I would also like to thank you guys for all the informative, critical and objective insights. Let's stay positive on the future of this company, which has a huge potential, if this and that.. :-) All the best for 2022, and most importantly stay healthy.
ElTorro Enjoy the break. Have a happy New Year! FL
An interview with ImmunExpress' CEO.www.dnaweekly.com/blog/immunexpress-i... A couple things jump out: 1) They are planning on rollout of Septicyte Rapid in 2022 (i.e., it did not initiate it upon FDA approval in November). The time lag may be related to the reagent shortage we have discussed on the board. Presumably they are now building inventory in the US in anticipation of the rollout. 2) The ImmunExpress rollout is constrained by funding availability. Diapharm was/is an early investor. They made a cash infusion about 2 years ago to fund the development of Septicyte Rapid, I'm surprised an additional round of funding has not been announced. 3)They are already working on the next generation Septicyte Rapid. FL
Andere jaren werd er begin januari middels een persbericht bekendgemaakt of de jaardoelstelling behaald is., incl de daadwerkelijke verkoop cijfers. Gaat er dit jaar ook zo'n persbericht komen ?, voorgaande jaren meestal rond 10/11 januari, op de site/agenda van Biocartis kan ik er niks over vinden.
Hopelijk doen ze dit inderdaad opnieuw. Zou ons al een goed idee geven van hoe ze hersteld zijn van de brand en hoe groot de eventuele problemen met grondstoffen zijn.
chicago.cbslocal.com/2021/12/28/chica... This is why I've said that this is a good environment for BCART (assuming that BCART can secure a raw reagent supply). All of those PCR tests are likely to overwelm some labs. Idylla's shelf stable, on demand use profile, with little hands on technician time is ideal for this environment. Especially as oncology testing picks up. So any opinions of whether this is the year that management finally starts delivering on expectations? I consider this a pivotal year and will I'll be re-evaluating management performance throughout the next 12 months. If they cannot show substantial progress with the current tailwinds, it will be time to throw in the towel. Here is a short list of milestones I'd like to see in 2022: 1)Release of the revamped EGFR assay that resolves the T790 mutation issue. This is likely to be in the Braf-EGFR combo assay; 2) FDA approval of the MSI 510K and launch (non RUO) in the US; 4) SkylineDx initiating validation of the Merlin Assay for nodal metastasis in melanoma. Note this program seems to be on an accelerated timeline since Skyline is incharge of the R&D associated with developing the assay; 3) Successful launch of Septicyte rapid in the US; 4) Announcement of ML3 completion and start up testing, and news that it was accomplished under budget; 5) China registration approval for the 3 assays that were filed (MSI, Braf & EGFR) & announcement of BMS launch support for the MSI assay; 6) Japan registration approval news; 7) News that a reliable reagent sourcing has been secured; 8) News of a funding plan with limited dilution impacts. Perhaps that Cathy wood's Ark funds have established positions in BCART (Additional shares were authorized at the last A.M). She brings quite a Reddit following that would create upward pressure on the SP; 9) News of Kite or other partner validation testing news;www.thestreet.com/investing/cathie-wo... Okay so I slipped a wishful item along with some of the more realistic milestones. Happy New Year! FL
Thanks,FL,a happy new year.
Immunexpress is providing an update on Septicyte Rapid commercialization plans (See below). FL Immunexpress CEO To Present at the Virtual Biotech Showcase 2022 SEATTLE, Jan. 4, 2022 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022. Dr. Carlson will present an overview of Immunexpress' SeptiCyte® technology and a corporate update on commercial plans for newly FDA cleared sepsis diagnostic SeptiCyte® RAPID. Dr. Carlson is available for virtual meetings.
Great, thanks for the news. At least a bit of insights then.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee